[go: up one dir, main page]

MA62935B1 - Méthodes de traitement ou de prévention de l'amyotrophie spinale - Google Patents

Méthodes de traitement ou de prévention de l'amyotrophie spinale

Info

Publication number
MA62935B1
MA62935B1 MA62935A MA62935A MA62935B1 MA 62935 B1 MA62935 B1 MA 62935B1 MA 62935 A MA62935 A MA 62935A MA 62935 A MA62935 A MA 62935A MA 62935 B1 MA62935 B1 MA 62935B1
Authority
MA
Morocco
Prior art keywords
methods
prevention
treatment
spinal amyotrophy
amyotrophy
Prior art date
Application number
MA62935A
Other languages
English (en)
Inventor
Kenneth Swope Loveday
Fengju Judy Bai
Lilly East
Wildon R Farwell
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA62935(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA62935B1 publication Critical patent/MA62935B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)

Abstract

L'invention concerne des procédés pour le traitement ou la prévention de l'amyotrophie spinale. Des schémas posologiques efficaces sont spécifiés. L'invention concerne également des biomarqueurs et des kits.
MA62935A 2019-07-19 2020-07-16 Méthodes de traitement ou de prévention de l'amyotrophie spinale MA62935B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962876360P 2019-07-19 2019-07-19

Publications (1)

Publication Number Publication Date
MA62935B1 true MA62935B1 (fr) 2023-11-30

Family

ID=71995097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62935A MA62935B1 (fr) 2019-07-19 2020-07-16 Méthodes de traitement ou de prévention de l'amyotrophie spinale

Country Status (33)

Country Link
US (3) US20220325282A1 (fr)
EP (2) EP3999643B1 (fr)
JP (3) JP7279253B2 (fr)
KR (1) KR20220042113A (fr)
CN (1) CN114302727A (fr)
AR (1) AR119430A1 (fr)
AU (1) AU2020316997A1 (fr)
BR (1) BR112022000870A2 (fr)
CA (1) CA3149906A1 (fr)
CL (1) CL2021003602A1 (fr)
CO (1) CO2022001354A2 (fr)
CR (1) CR20220071A (fr)
DK (1) DK3999643T5 (fr)
ES (1) ES2966791T3 (fr)
FI (1) FI3999643T3 (fr)
HR (1) HRP20231515T1 (fr)
HU (1) HUE064071T2 (fr)
IL (1) IL289745A (fr)
JO (1) JOP20220007A1 (fr)
LT (1) LT3999643T (fr)
MA (1) MA62935B1 (fr)
MD (1) MD3999643T2 (fr)
MX (1) MX2022000441A (fr)
PE (1) PE20220941A1 (fr)
PH (1) PH12022550114A1 (fr)
PL (1) PL3999643T3 (fr)
PT (1) PT3999643T (fr)
RS (1) RS64879B1 (fr)
SI (1) SI3999643T1 (fr)
SM (1) SMT202300442T1 (fr)
TW (2) TW202438086A (fr)
UY (1) UY38790A (fr)
WO (1) WO2021016032A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2016040748A1 (fr) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions et procédés de détection d'une protéine smn chez un patient et traitement d'un patient
PL3999643T3 (pl) 2019-07-19 2024-02-19 Biogen Ma Inc. Sposoby leczenia rdzeniowego zaniku mięśni i zapobiegania mu
WO2024138018A1 (fr) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Traitement de troubles induits par gemin5

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1910395T3 (pl) 2005-06-23 2013-03-29 Cold Spring Harbor Laboratory Kompozycja i sposób modulacji splicingu SMN2
WO2008157753A1 (fr) * 2007-06-21 2008-12-24 Sma Foundation Procédés de traitement d'une atrophie musculaire spinale
CN115227710A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
WO2011032109A1 (fr) 2009-09-11 2011-03-17 Sma Foundation Biomarqueurs de l'atrophie musculaire spinale
WO2012160130A1 (fr) * 2011-05-25 2012-11-29 Universite Paris Descartes Inhibiteurs de la voie erk pour le traitement de l'amyotrophie spinale
WO2014110291A1 (fr) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions et procédés pour la modulation de l'épissage de smn2 chez un sujet
WO2016040748A1 (fr) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions et procédés de détection d'une protéine smn chez un patient et traitement d'un patient
EP4206213A1 (fr) * 2016-07-15 2023-07-05 Ionis Pharmaceuticals, Inc. Composés et procédés de modulation de smn2
TW201927241A (zh) 2017-12-21 2019-07-16 瑞士商赫孚孟拉羅股份公司 用於肌肉失能之數位生物標記
IL276180B2 (en) 2018-01-25 2025-07-01 Biogen Ma Inc Methods of treating spinal muscular atrophy
IT201800004359A1 (it) 2018-04-10 2019-10-10 IDENTIFICAZIONE DI miRNA MUSCOLARI COME BIOMARCATORI E TRATTAMENTO CO-ADIUVANTE PER L’ATROFIA MUSCOLARE SPINALE
EP3837374A4 (fr) * 2018-08-15 2022-06-08 Biogen MA Inc. Polythérapie pour atrophie musculaire spinale
PL3999643T3 (pl) 2019-07-19 2024-02-19 Biogen Ma Inc. Sposoby leczenia rdzeniowego zaniku mięśni i zapobiegania mu

Also Published As

Publication number Publication date
BR112022000870A2 (pt) 2022-03-22
PL3999643T3 (pl) 2024-02-19
CO2022001354A2 (es) 2022-03-18
HUE064071T2 (hu) 2024-02-28
LT3999643T (lt) 2023-12-11
CL2021003602A1 (es) 2022-10-14
FI3999643T3 (fi) 2023-11-30
SI3999643T1 (sl) 2024-01-31
AU2020316997A1 (en) 2022-03-10
JP2023100911A (ja) 2023-07-19
US20240318182A1 (en) 2024-09-26
CR20220071A (es) 2022-04-22
HRP20231515T1 (hr) 2024-03-01
CA3149906A1 (fr) 2021-01-28
ES2966791T3 (es) 2024-04-24
IL289745A (en) 2022-03-01
WO2021016032A1 (fr) 2021-01-28
PT3999643T (pt) 2023-12-11
JP2025096486A (ja) 2025-06-26
DK3999643T5 (da) 2024-08-05
EP3999643A1 (fr) 2022-05-25
EP4335503A3 (fr) 2024-06-05
MX2022000441A (es) 2022-03-25
JP7279253B2 (ja) 2023-05-22
US20250230440A1 (en) 2025-07-17
AR119430A1 (es) 2021-12-15
US20220325282A1 (en) 2022-10-13
DK3999643T3 (da) 2023-12-04
EP3999643B1 (fr) 2023-11-22
JP2022540993A (ja) 2022-09-21
JP7665678B2 (ja) 2025-04-21
SMT202300442T1 (it) 2024-01-10
PH12022550114A1 (en) 2023-04-17
KR20220042113A (ko) 2022-04-04
TWI841762B (zh) 2024-05-11
TW202438086A (zh) 2024-10-01
CN114302727A (zh) 2022-04-08
TW202116331A (zh) 2021-05-01
JOP20220007A1 (ar) 2023-01-30
EP4335503A2 (fr) 2024-03-13
UY38790A (es) 2021-01-29
PE20220941A1 (es) 2022-05-31
MD3999643T2 (ro) 2024-02-29
RS64879B1 (sr) 2023-12-29

Similar Documents

Publication Publication Date Title
MA62935B1 (fr) Méthodes de traitement ou de prévention de l'amyotrophie spinale
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MA53937B1 (fr) Compositions comprenant des souches bactériennes
MA42279A (fr) Compositions comprenant une souche bactérienne de blautia hydrogenotrophica pour l'utilisation pour la prevention ou le traitement de la diarrhee ou la constipation
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
MA42560B1 (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MA50406B1 (fr) Inhibiteurs pyrazole de magl
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
EP4445913A3 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie liée à c5 et procédé de traitement ou de prévention d'une maladie liée à c5
EP4285993A3 (fr) Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
EA202192961A1 (ru) Ребамипид для применения в профилактике и/или лечении синуклеинопатий
MX2020007619A (es) Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
WO2020185651A3 (fr) Compositions et méthodes de traitement de la maladie de huntington
WO2018141313A3 (fr) Utilisation de composés fgf-4
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn
WO2021136841A3 (fr) Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
ZA202203504B (en) Rebamipide for use in prophylaxis and treatment of cancer